Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

SAN ANTONIO — Futibatinib plus fulvestrant exhibited antitumor activity among certain patients with locally advanced or metastatic breast cancer with fibroblast growth factor receptor 1 ...

The patients were randomly assigned to receive alisertib monotherapy (n=46) or alisertib plus fulvestrant (n=45). Prior chemotherapy for metastatic disease was more common in the combination arm ...

PATIENTS AND METHODS: Patients (n = 451) with advanced breast cancer were randomized to receive fulvestrant 250 mg as a once-monthly (one × 5 mL) intramuscular injection or an oral dose of anastrozole ...

References: Capivasertib in combination with Faslodex ® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer. News release. June 12, 2023. https ...

Fulvestrant has demonstrated efficacy in the treatment of postmenopausal women with advanced, hormone-sensitive breast cancer, with data indicating that fulvestrant exhibits this activity in both ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...